“We need all stakeholders to be all in on biosimilars…now’s the time for people to get engaged and get out there to support uptake and access,” says our guest, Juliana Reed, president of Biosimilars Forum.
Last week on the podcast, we brought you an industry perspective on biosimilars with a discussion of how manufacturers think about pricing their products for the marketplace. This week, we’re changing gears with a discussion of how that marketplace is working.
Our guest this week is Juliana Reed, president of Biosimilars Forum.
The Biosimilars Forum is a nonprofit organization that seeks to raise awareness of biosimilars and provide an opportunity for developers to work together with other stakeholders on relevant topics in the industry. The founding members of the Biosimilars Forum include many of the companies with significant US biosimilar development portfolios.
Reed joined The Center for Biosimilars® by phone to discuss reimbursement, policy, and what it takes to create a vibrant marketplace for cost-saving biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.